Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 201–300 of 1,002
Immunogenicity of rituximab in patients with severe pemphigus
Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., & Kromminga, A. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.05.007 · Cited by 96
Effect of blood type on anti-α-Gal immunity and the incidence of infectious diseases
Cabezas-Cruz, A., Mateos-Hernández, L., Alberdi, P., Villar, M., Riveau, G., Hermann, E., Schacht, A.-M., Khalife, J., Correia-Neves, M., Gortazar, C., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.164 · Cited by 91
Füssl, F., Trappe, A., Carillo, S., Jakes, C., & Bones, J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00185 · Cited by 95
Anaphylaxis to the Carbohydrate Side Chain Alpha-gal
Platts-Mills, T. A. E., Schuyler, A. J., Tripathi, A., & Commins, S. P. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.01.009 · Cited by 96
Self-citationMazor, R., & Pastan, I. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01261 · Cited by 94
Chartrain, M. M., & Chu, L. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786367 · Cited by 108
van Berkel, P. H. C., Gerritsen, J., Perdok, G., Valbjørn, J., Vink, T., van de Winkel, J. G. J., & Parren, P. W. H. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.92 · Cited by 92
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Doevendans, E., & Schellekens, H. (2019) · Antibodies · doi:10.3390/antib8010021 · Cited by 101
Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies
Hong, D. I., Bankova, L. G., Cahill, K. N., Kyin, T., & Castells, M. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.75 · Cited by 93
How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations
Jahn, E., & Schneider, C. K. (2009) · New Biotechnology · doi:10.1016/j.nbt.2009.03.012 · Cited by 93
Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy
Saylor, K., Gillam, F., Lohneis, T., & Zhang, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00283 · Cited by 89
Zhang, J., Shan, L., Liang, F., Du, C.-Y., & Li, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.856049 · Cited by 97
Arkestål, K., Sibanda, E., Thors, C., Troye‐Blomberg, M., Mduluza, T., Valenta, R., Grönlund, H., & van Hage, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.033 · Cited by 92
The carbohydrate galactose-α-1,3-galactose is a major IgE-binding epitope on cat IgA
Grönlund, H., Adédoyin, J., Commins, S. P., Platts-Mills, T. A. E., & van Hage, M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.011 · Cited by 91
Self-citationPost-translational modification of plant-made foreign proteins; glycosylation and beyond
Webster, D. E., & Thomas, M. C. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.07.015 · Cited by 90
Management of Food Allergies and Food-Related Anaphylaxis
Iglesia, E. G. A., Kwan, M., Virkud, Y. V., & Iweala, O. I. (2024) · JAMA · doi:10.1001/jama.2023.26857 · Cited by 89
Borys, M. C., Dalal, N. G., Abu‐Absi, N. R., Khattak, S. F., Jing, Y., Xing, Z., & Li, Z. J. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22644 · Cited by 83
Adverse Reactions to Biologic Therapy
Patel, S. V., & Khan, D. A. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.012 · Cited by 89
Hashizume, H., Fujiyama, T., Umayahara, T., Kageyama, R., Walls, A. F., & Satoh, T. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.028 · Cited by 84
Clinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87
Álvarez-Cuesta, E., Madrigal‐Burgaleta, R., Broyles, A. D., Cuesta‐Herranz, J., Guzman-Melendez, M. A., Maciag, M. C., Phillips, E. J., Trubiano, J. A., Wong, J. T., Ansotegui, I. J., et al. (2022) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100640 · Cited by 99
Hmiel, L. K., Brorson, K., & Boyne, M. T. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8108-x · Cited by 92
Apostolovic, D., Tran, T. A. T., Hamsten, C., Starkhammar, M., Cirkovic Velickovic, T., & van Hage, M. (2014) · Allergy · doi:10.1111/all.12462 · Cited by 87
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 93
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 91
The Immunogenicity of Biologic Therapies
Garcês, S., & Demengeot, J. (2017) · Current problems in dermatology · doi:10.1159/000478077 · Cited by 94
Synthetic Glycobiology: Parts, Systems, and Applications
Kightlinger, W., Warfel, K. F., DeLisa, M. P., & Jewett, M. C. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00210 · Cited by 94
Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
Guan, M., Zhou, Y., Sun, J., & Chen, S.-C. (2015) · BioMed Research International · doi:10.1155/2015/428169 · Cited by 86
Using glyco-engineering to produce therapeutic proteins
Dicker, M., & Strasser, R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1069271 · Cited by 90
Pre-existing antibody: biotherapeutic modality-based review
Gorovits, B., Clements-Egan, A., Birchler, M., Liang, M., Myler, H., Peng, K., Purushothama, S., Rajadhyaksha, M., Salazar-Fontana, L., Sung, C., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9878-1 · Cited by 85
Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack
Sharma, S. R., & Karim, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.680264 · Cited by 95
Galli, S. J. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.07.025 · Cited by 89
Okerblom, J., & Varki, A. (2017) · ChemBioChem · doi:10.1002/cbic.201700077 · Cited by 79
Castells, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01472 · Cited by 90
Allergenicity of Carbohydrates and Their Role in Anaphylactic Events
Commins, S. P., & Platts-Mills, T. A. E. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-009-0079-1 · Cited by 83
Self-citationBiacchi, M., Gahoual, R., Said, N., Beck, A., Leize-Wagner, E., & François, Y.-N. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00928 · Cited by 79
MS‐based glycomics and glycoproteomics methods enabling isomeric characterization
Peng, W., Reyes, C. D. G., Gautam, S., Yu, A., Cho, B. G., Goli, M., Donohoo, K. B., Mondello, S., Kobeissy, F. H., & Mechref, Y. S. (2021) · Mass Spectrometry Reviews · doi:10.1002/mas.21713 · Cited by 87
Stepping stones in DNA sequencing
Stranneheim, H., & Lundeberg, J. (2012) · Biotechnology Journal · doi:10.1002/biot.201200153 · Cited by 94
Galactose-α-1,3-Galactose–Specific IgE Is Associated with Anaphylaxis but Not Asthma
Commins, S. P., Kelly, L. A., Rönmark, E., James, H. R., Pochan, S. L., Peters, E. J., Lundbäck, B., Nganga, L., Cooper, P. J., Hoskins, J. M., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201111-2017oc · Cited by 87
Self-citationLargy, E., Cantais, F., Vyncht, G. V., Beck, A., & Delobel, A. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.02.072 · Cited by 84
In Vitro Diagnosis of Immediate Drug Hypersensitivity During Anesthesia: A Review of the Literature
Ebo, D. G., Faber, M. A., Elst, J., Gasse, A. L. V., Bridts, C. H., Mertens, C. H., Clerck, L. S. D., Hagendorens, M. M., & Sabato, V. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.01.004 · Cited by 88
The α-Gal Syndrome and Potential Mechanisms
Román‐Carrasco, P., Hemmer, W., Cabezas‐Cruz, A., Hodžić, A., de la Fuente, J., & Swoboda, I. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.783279 · Cited by 96
Wilson, J. M., Erickson, L. D., Levin, M. E., Ailsworth, S. M., Commins, S. P., & Platts‐Mills, T. A. E. (2024) · Allergy · doi:10.1111/all.16003 · Cited by 90
Self-citationCross-reactivity syndromes in food allergy.
García, B. E., & Lizaso, M. T. (2011) · PubMed · Cited by 82
Holland, M. C., Würthner, J., Morley, P. J., Birchler, M., Lambert, J., Albayaty, M., Serone, A., Wilson, R., Chen, Y., Forrest, R. M., et al. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9915-0 · Cited by 82
Allergens, sources, particles, and molecules: Why do we make IgE responses?
Woodfolk, J. A., Commins, S. P., Schuyler, A. J., Erwin, E. A., & Platts-Mills, T. A. E. (2015) · Allergology International · doi:10.1016/j.alit.2015.06.001 · Cited by 75
Self-citationPotential deleterious role of anti‐Neu5Gc antibodies in xenotransplantation
Salama, A., Evanno, G., Harb, J., & Soulillou, J. (2015) · Xenotransplantation · doi:10.1111/xen.12142 · Cited by 81
Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
Wadlow, R. C., Hezel, A. F., Abrams, T. A., Blaszkowsky, L. S., Fuchs, C. S., Kulke, M. H., Kwak, E. L., Meyerhardt, J. A., Ryan, D. P., Szymonifka, J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0452 · Cited by 80
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
Li, W., Zhu, Z., Chen, W., Feng, Y., & Dimitrov, D. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01554 · Cited by 78
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context
Bloem, K., Hernández‐Breijo, B., Martínez‐Feito, A., & Rispens, T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000404 · Cited by 81
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
Beck, A., Cochet, O., & Wurch, T. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903413504 · Cited by 77
Maeda, E., Kita, S., Kinoshita, M., Urakami, K., Hayakawa, T., & Kakehi, K. (2012) · Analytical Chemistry · doi:10.1021/ac300234a · Cited by 82
Food Allergy: Our Evolving Understanding of Its Pathogenesis, Prevention, and Treatment
Iweala, O. I., & Burks, A. W. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0616-7 · Cited by 89
Blank, S., Bantleon, F. I., McIntyre, M., Ollert, M., & Spillner, E. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2012.03966.x · Cited by 76
Delayed mammalian meat–induced anaphylaxis due to galactose-α-1,3-galactose in 5 European patients
Núñez, R., Carballada, F., González‐Quintela, A., Rial, J. G., Boquete, M., & Vidal, C. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.020 · Cited by 101
Galactose α-1,3-galactose phenotypes
Levin, M., Apostolovic, D., Biedermann, T., Commins, S. P., Iweala, O. I., Platts-Mills, T. A. E., Savi, E., van Hage, M., & Wilson, J. M. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.03.021 · Cited by 77
Self-citationComponent-Resolved Diagnosis in Food Allergies
Calamelli, E., Liotti, L., Beghetti, I., Piccinno, V., Serra, L., & Bottau, P. (2019) · Medicina · doi:10.3390/medicina55080498 · Cited by 85
Helminth therapies: Translating the unknown unknowns to known knowns
Khan, A. R., & Fallon, P. G. (2013) · International Journal for Parasitology · doi:10.1016/j.ijpara.2012.12.002 · Cited by 73
Clinical immunotoxicity of therapeutic proteins
Descotes, J., & Gouraud, A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802525496 · Cited by 77
Galactose-α-1,3-Galactose: Atypical Food Allergen or Model IgE Hypersensitivity?
Wilson, J. M., Schuyler, A. J., Schroeder, N., & Platts-Mills, T. A. E. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0672-7 · Cited by 74
Self-citationGlycoengineered antibodies: towards the next-generation of immunotherapeutics
Mastrangeli, R., Palinsky, W., & Bierau, H. (2018) · Glycobiology · doi:10.1093/glycob/cwy092 · Cited by 84
Carbohydrate epitopes currently recognized as targets for IgE antibodies
Platts‐Mills, T. A., Hilger, C., Jappe, U., van Hage, M., Gadermaier, G., Spillner, E., Lidholm, J., Keshavarz, B., Aalberse, R. C., van Ree, R., et al. (2021) · Allergy · doi:10.1111/all.14802 · Cited by 71
Self-citationMatucci, A., Pratesi, S., Petroni, G., Nencini, F., Virgili, G., Milla, M., Maggi, E., & Vultaggio, A. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12098 · Cited by 76
Alpha-Gal-containing biologics and anaphylaxis
Chinuki, Y., & Morita, E. (2019) · Allergology International · doi:10.1016/j.alit.2019.04.001 · Cited by 78
Allergic response to medical products in patients with alpha-gal syndrome
Kuravi, K. V., Sorrells, L. T., Nellis, J. R., Rahman, F., Walters, A. H., Matheny, R. G., Choudhary, S. K., Ayares, D. L., Commins, S. P., Bianchi, J. R., et al. (2022) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.03.100 · Cited by 72
Considerations for the development of therapeutic monoclonal antibodies
Swann, P. G., Tolnay, M., Muthukkumar, S., Shapiro, M. A., Rellahan, B. L., & Clouse, K. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.013 · Cited by 78
Edwards, E., Livanos, M., Krueger, A., Dell, A., Haslam, S. M., Smales, C. M., & Bracewell, D. G. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28066 · Cited by 80
Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Vultaggio, A., Maggi, E., & Matucci, A. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283464bcd · Cited by 74
Hilger, C., Fischer, J., Swiontek, K., Hentges, F., Lehners, C., Eberlein, B., Morisset, M., Biedermann, T., & Ollert, M. (2016) · Allergy · doi:10.1111/all.12835 · Cited by 73
The changing face of anaphylaxis in adults and adolescents
Pattanaik, D., Lieberman, P., Lieberman, J., Pongdee, T., & Keene, A. T. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.07.017 · Cited by 68
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
Eng, C. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.16 · Cited by 81
Mast cells and IgE in defense against venoms: Possible “good side” of allergy?
Galli, S. J., Starkl, P., Marichal, T., & Tsai, M. (2016) · Allergology International · doi:10.1016/j.alit.2015.09.002 · Cited by 73
Host cell proteins in biotechnology‐derived products: A risk assessment framework
de Zafra, C. L. Z., Quarmby, V. E., Francissen, K., Vanderlaan, M., & Zhu-Shimoni, J. X. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25647 · Cited by 73
Gahoual, R., Biacchi, M., Chicher, J., Kuhn, L., Hammann, P., Beck, A., Leize-Wagner, E., & François, Y. N. (2014) · mAbs · doi:10.4161/mabs.36305 · Cited by 69
Anesthesia in the patient with multiple drug allergies: are all allergies the same?
Dewachter, P., Mouton‐Faivre, C., Castells, M., & Hepner, D. L. (2011) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3283466c13 · Cited by 77
Immunogenicity of biological therapeutics: from assay to patient
Krieckaert, C. L. M., Rispens, T., & Wolbink, G. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283521c4e · Cited by 73
Homann, A., Schramm, G., & Jappe, U. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.019 · Cited by 75
Xu, W., Jimenez, R. B., Mowery, R., Luo, H., Cao, M., Agarwal, N., Ramos, I., Wang, X., & Wang, J. (2017) · mAbs · doi:10.1080/19420862.2017.1364326 · Cited by 71
Pro: The Evidence for a Causal Role of Dust Mites in Asthma
Platts‐Mills, T. A. E., Erwin, E. A., Heymann, P. W., & Woodfolk, J. A. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200811-1756pr · Cited by 76
Self-citationMajewska, N. I., Tejada, M. L., Betenbaugh, M. J., & Agarwal, N. (2020) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-102419-010001 · Cited by 81
Bioengineering of Antibody Fragments: Challenges and Opportunities
Pirkalkhoran, S., Grabowska, W. R., Kashkooli, H. H., Mirhassani, R., Guiliano, D. B., Dolphin, C. T., & Khalili, H. (2023) · Bioengineering · doi:10.3390/bioengineering10020122 · Cited by 79
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., Gómez de la Cuesta, R., Gallagher, T. R. A., Michael, R., Stallwood, Y., Ekblad, C., Abrahmsén, L., et al. (2015) · BioMed Research International · doi:10.1155/2015/605427 · Cited by 66
Agostino, M., Jene, C., Boyle, T., Ramsland, P. A., & Yuriev, E. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900388a · Cited by 72
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Carethers, J. M. (2008) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08093607 · Cited by 82
Stubenrauch, K. G., Wessels, U., Birnboeck, H., Ramirez, F. C., Jahreis, A., & Schleypen, J. S. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.021 · Cited by 75
Identification of alpha‐gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis
Carter, M. C., Ruiz‐Esteves, K. N., Workman, L., Lieberman, P., Platts‐Mills, T. A. E., & Metcalfe, D. D. (2018) · Allergy · doi:10.1111/all.13366 · Cited by 71
Self-citationDiagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018
Binder, A. M., Commins, S. P., Altrich, M. L., Wachs, T., Biggerstaff, B. J., Beard, C. B., Petersen, L. R., Kersh, G. J., & Armstrong, P. A. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.12.019 · Cited by 63
The Value of In Vitro Tests to Diminish Drug Challenges
Mayorga, C., Doña, I., Pérez‐Inestrosa, E., Fernández, T. D., & Torres, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061222 · Cited by 72
Anaesthetic management of patients with pre-existing allergic conditions: a narrative review
Dewachter, P., Kopač, P., Laguna, J. J., Mertès, P., Sabato, V., Volcheck, G. W., & Cooke, P. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.01.020 · Cited by 77
Red meat allergy in children and adults
Wilson, J. M., & Platts‐Mills, T. A. E. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000523 · Cited by 74
Self-citationDrug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Petroni, G., Cammelli, D., Alterini, R., Rigacci, L., Romagnani, S., & Maggi, E. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000336839 · Cited by 69
Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
Yang, B., Lum, P., Chen, A., Arends, R., Roskos, L. K., Smith, B. P., & Ruixo, J. J. P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535970-000000000-00000 · Cited by 74
Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans
Everds, N. E., & Tarrant, J. M. (2013) · Toxicologic Pathology · doi:10.1177/0192623312467400 · Cited by 69
Improving Immunotherapy Through Glycodesign
Buettner, M. J., Shah, S. R., Saeui, C. T., Ariss, R., & Yarema, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02485 · Cited by 70
A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease
Portillo, S., Zepeda, B. G., Iniguez, E., Olivas, J. J., Karimi, N. H., Moreira, O. C., Marques, A. F., Michael, K., Maldonado, R. A., & de Almeida, I. C. (2019) · npj Vaccines · doi:10.1038/s41541-019-0107-7 · Cited by 68
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
The Significance of Glycosylation Analysis in Development of Biopharmaceuticals
Kawasaki, N., Itoh, S., Hashii, N., Takakura, D., Qin, Y., Huang, X., & Yamaguchi, T. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.796 · Cited by 67
Masilamani, M., Commins, S. P., & Shreffler, W. G. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2011.12.003 · Cited by 76
Monoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulovic, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 61
The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins
O’Flaherty, R., Trbojević‐Akmačić, I., Greville, G., Rudd, P. M., & Lauc, G. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1404907 · Cited by 70
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.